Mannoside Glycolipid Conjugates Display Antiviral Activity Against Ebola Virus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30239745.
- Also identified by DOI 10.1093/infdis/jiy464.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The West African outbreak of Ebola virus (EBOV) infection during 2013-2016 highlighted the need for development of field-applicable therapeutic drugs for this infection. Here we report that mannoside glycolipid conjugates (MGCs) consisting of a trimannose head and a lipophilic chain assembled by a linker inhibit EBOV infection not only of human monocyte-derived dendritic cells and macrophages, but also of a number of susceptible cells. Analysis of the mode of action leads us to conclude that MGCs act directly on cells, notably by preventing virus endocytosis.
Medical subject headings
- Antiviral Agents
- Ebolavirus
- Glycolipids
- Mannosides